For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Protalix BioTherapeutics Inc (AMEX: PLX) closed at $2.57 in the last session, up 2.80% from day before closing price of $2.5. In other words, the price has increased by $2.80 from its previous closing price. On the day, 0.59 million shares were traded. PLX stock price reached its highest trading level at $2.5989 during the session, while it also had its lowest trading level at $2.53.
Ratios:
We take a closer look at PLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 2.72. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 10 ’25 when Schwartz Aharon bought 129,000 shares for $1.60 per share. The transaction valued at 205,884 led to the insider holds 303,000 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLX now has a Market Capitalization of 204911520 and an Enterprise Value of 171281280. As of this moment, Protalix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 34.73, and their Forward P/E ratio for the next fiscal year is 4.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.31 while its Price-to-Book (P/B) ratio in mrq is 4.11. Its current Enterprise Value per Revenue stands at 2.765 whereas that against EBITDA is 17.849.
Stock Price History:
The Beta on a monthly basis for PLX is -0.20, which has changed by 1.5699999 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, PLX has reached a high of $3.10, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is 43.99%, while the 200-Day Moving Average is calculated to be 27.37%.
Shares Statistics:
According to the various share statistics, PLX traded on average about 696.54K shares per day over the past 3-months and 891050 shares per day over the past 10 days. A total of 79.73M shares are outstanding, with a floating share count of 76.01M. Insiders hold about 4.67% of the company’s shares, while institutions hold 15.63% stake in the company. Shares short for PLX as of 1757894400 were 3661372 with a Short Ratio of 5.26, compared to 1755216000 on 3761613. Therefore, it implies a Short% of Shares Outstanding of 3661372 and a Short% of Float of 4.79.
Earnings Estimates
The stock of Protalix BioTherapeutics Inc (PLX) is currently drawing attention from 2.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.04, with high estimates of $0.05 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.21 and $0.05 for the fiscal current year, implying an average EPS of $0.13. EPS for the following year is $0.55, with 2.0 analysts recommending between $0.74 and $0.35.
Revenue Estimates
According to 2 analysts,. The current quarter’s revenue is expected to be $17.87M. It ranges from a high estimate of $18.17M to a low estimate of $17.56M. As of. The current estimate, Protalix BioTherapeutics Inc’s year-ago sales were $17.84MFor the next quarter, 2 analysts are estimating revenue of $16.92M. There is a high estimate of $18.58M for the next quarter, whereas the lowest estimate is $15.26M.
A total of 2 analysts have provided revenue estimates for PLX’s current fiscal year. The highest revenue estimate was $61.91M, while the lowest revenue estimate was $59.2M, resulting in an average revenue estimate of $60.55M. In the same quarter a year ago, actual revenue was $53.4MBased on 2 analysts’ estimates, the company’s revenue will be $106.44M in the next fiscal year. The high estimate is $119.46M and the low estimate is $93.41M.
